Pathological and Oncological Outcomes of Elderly Men with Clinically Localized Prostate Cancer

被引:3
|
作者
Mitsuzuka, Koji [1 ,2 ]
Koie, Takuya [2 ,3 ]
Narita, Shintaro [2 ,4 ]
Kaiho, Yasuhiro [1 ,2 ]
Yoneyama, Takahiro [2 ,3 ]
Tsuchiya, Norihiko [2 ,4 ]
Kakoi, Narihiko [2 ,5 ]
Kawamura, Sadafumi [2 ,5 ]
Tochigi, Tatsuo [2 ,5 ]
Ohyama, Chikara [2 ,3 ]
Habuchi, Tomonori [2 ,4 ]
Arai, Yoichi [1 ,2 ]
机构
[1] Tohoku Univ, Grad Sch Med, Dept Urol, Sendai, Miyagi 9808574, Japan
[2] Michinoku Japan Urol Canc Study Grp, Sendai, Miyagi, Japan
[3] Hirosaki Univ, Grad Sch Med, Dept Urol, Hirosaki, Aomori, Japan
[4] Akita Univ, Dept Urol, Grad Sch Med, Akita 010, Japan
[5] Miyagi Canc Ctr, Dept Urol, Natori, Miyagi 9811293, Japan
关键词
radical prostatectomy; elderly; oncological outcome; age; ASSISTED RADICAL PROSTATECTOMY; VOLUME; METAANALYSIS; THERAPY; LIFE; AGE;
D O I
10.1093/jjco/hyt143
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of the study was to characterize pathological and oncological outcomes of elderly men with clinically localized prostate cancer treated with radical prostatectomy. Data from 1268 patients undergoing radical prostatectomy between 2000 and 2009 were retrospectively reviewed. Patients were classified according to whether they were of age 70 or 70 years at radical prostatectomy. Patient characteristics, pathological and oncological outcomes were compared among the groups. Of the total population, 31.4 (398 of 1268) of patients were 70 years of age. The median age in patients 70 and 70 years of age was 64 (4569) and 72 (7083) years. The proportion of low-risk disease was significantly lower among those 70 years of age than in those 70 years, while the proportion of high-risk disease was significantly higher among those 70 years of age than in those 70 years (P 0.001). The proportions of pathological high-risk disease (T3b, GS 8, positive surgical margin or lymph node invasion) in patients 70 and 70 years of age were 42.0 and 50.0, respectively (P 0.008). The proportions of organ-confined disease in patients 70 and 70 years of age were 69.9 and 65.1, respectively (P 0.09). With a median follow-up of 50 months, 5-year biochemical recurrence-free and cancer-specific survival rates were not significantly different among the groups. Radical prostatectomy was more likely to be performed in those with higher-risk disease among patients 70 years of age. About half of the patients 70 years of age had pathological, high-risk disease. Radical prostatectomy could be considered for patients with expected long-term life expectancy, even in the setting of advanced age.
引用
收藏
页码:1238 / 1242
页数:5
相关论文
共 50 条
  • [1] Does the type of cryoprobe affect oncological and functional outcomes in men with clinically localized prostate cancer treated with primary whole gland prostate cryoablation?
    Taha, Tarek
    Tan, Wei Phin
    Elshafei, Ahmed
    Aminsharifi, Alireza
    Given, Robert
    Cher, Michael L.
    Polascik, Thomas J.
    [J]. CURRENT UROLOGY, 2021, 15 (02) : 79 - 84
  • [2] Outcomes of treatment vs observation of localized prostate cancer in elderly men
    Porter, Michael P.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (15): : 1652 - 1652
  • [3] Surgical Delay and Pathological Outcomes for Clinically Localized High-Risk Prostate Cancer
    Xia, Leilei
    Talwar, Ruchika
    Chelluri, Raju R.
    Guzzo, Thomas J.
    Lee, Daniel J.
    [J]. JAMA NETWORK OPEN, 2020, 3 (12) : E2028320
  • [4] Roach's mathematical equations in predicting pathological stage in men with clinically localized prostate cancer
    Medica, M
    Giglio, M
    Germinale, F
    Timossi, L
    Romagnoli, A
    Bertolotto, F
    Carmignani, G
    [J]. TUMORI, 2001, 87 (03) : 130 - 133
  • [5] Pathological Characteristics of Prostate Cancer in Elderly Men
    Delongchamps, Nicolas B.
    Wang, Ching Y.
    Chandan, Vishal
    Jones, Richard F.
    Threatte, Gregory
    Jumbelic, Mary
    de la Roza, Gustavo
    Haas, Gabriel P.
    [J]. JOURNAL OF UROLOGY, 2009, 182 (03): : 927 - 930
  • [6] Testosterone as a predictor of pathological stage in clinically localized prostate cancer
    Isom-Batz, G
    Bianco, FJ
    Kattan, MW
    Mulhall, JP
    Lilja, H
    Eastham, JA
    [J]. JOURNAL OF UROLOGY, 2005, 173 (06): : 1935 - 1937
  • [7] Value of percent free prostate-specific antigen for the prediction of pathological stage in men with clinically localized prostate cancer
    Morote, J
    Trilla, E
    Esquena, S
    Serrallach, F
    Abascal, JM
    H'Mammed, YI
    de Torres, IM
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2002, 17 (04): : 239 - 243
  • [8] Prostatectomy and survival among men with clinically localized prostate cancer
    Lawrence, G
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (21): : 1724 - 1724
  • [9] Safety of purified isoflavones in men with clinically localized prostate cancer
    Kumar, Nagi B.
    Krischer, Jeffrey P.
    Allen, Kathy
    Riccardi, Diane
    Besterman-Dahan, Karen
    Salup, Raoul
    Kang, Lovellen
    Xu, Ping
    Pow-Sang, Julio
    [J]. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2007, 59 (02): : 169 - 175
  • [10] Predicting life expectancy in men with clinically localized prostate cancer
    Cowen, ME
    Halasyamani, LK
    Kattan, MW
    [J]. JOURNAL OF UROLOGY, 2006, 175 (01): : 99 - 103